Table 1 Antimicrobial and anticancer activities of synthesized bis-pyrimidine Schiff bases
From: Synthesis, molecular docking and biological evaluation of bis-pyrimidine Schiff base derivatives
Compounds | Minimum inhibitory concentration (MIC = µmol/mL) | IC50 = µmol/mL | ||||
|---|---|---|---|---|---|---|
Bacterial species | Fungal species | (HCT116) cancer cell line | ||||
Gram positive | Gram negative | C. albicans (MTCC 227) | A. niger (MTCC 281) | |||
B. subtilis (MTCC 441) | S. aureus (MTCC 3160) | E. coli (MTCC 443) | ||||
q1 | 0.83 | 0.83 | 1.65 | 0.41 | 1.65 | 0.18 |
q2 | 1.55 | 1.55 | 1.55 | 0.78 | 1.55 | 3.73 |
q3 | 1.75 | 1.75 | 1.75 | 0.87 | 1.75 | 3.64 |
q4 | 1.74 | 1.74 | 1.74 | 0.87 | 1.74 | 5.02 |
q5 | 1.80 | 1.80 | 1.80 | 0.90 | 1.80 | 2.31 |
q6 | 1.76 | 1.76 | 1.76 | 0.88 | 1.76 | 3.38 |
q7 | 1.75 | 1.75 | 1.75 | 0.87 | 1.75 | 5.59 |
q8 | 1.68 | 1.68 | 1.68 | 0.84 | 1.68 | 2.68 |
q9 | 1.90 | 1.90 | 1.90 | 1.90 | 1.90 | 7.61 |
q10 | 1.82 | 1.82 | 1.82 | 0.91 | 1.82 | >14.60 |
q11 | 1.85 | 1.85 | 1.85 | 0.92 | 1.85 | 6.79 |
q12 | 1.90 | 1.90 | 1.90 | 0.95 | 1.90 | 7.00 |
q13 | 1.82 | 1.82 | 1.82 | 0.46 | 1.82 | 2.92 |
q14 | 1.60 | 1.60 | 1.60 | 0.80 | 1.60 | 7.16 |
q15 | 1.60 | 1.60 | 1.60 | 1.60 | 1.60 | >12.79 |
q16 | 1.54 | 1.54 | 0.77 | 0.77 | 1.54 | 11.06 |
q17 | 1.80 | 1.80 | 1.80 | 0.45 | 1.80 | 10.09 |
q18 | 1.75 | 1.75 | 0.87 | 0.44 | 1.75 | 9.79 |
q19 | 1.63 | 1.63 | 0.81 | 0.41 | 1.63 | 11.73 |
q20 | 1.82 | 0.36 | 1.82 | 0.91 | 1.82 | >14.60 |
DMSO | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | – |
Norfloxacin | 0.47 | 0.47 | 0.47 | – | – | – |
Fluconazole | – | – | – | 0.50 | 0.50 | – |
5-Fluorouracil | – | – | – | – | – | 0.35 |